189 related articles for article (PubMed ID: 32166967)
1. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections.
Alvarez-Cardona JJ; Whited LK; Chemaly RF
Future Microbiol; 2020 Apr; 15():389-400. PubMed ID: 32166967
[TBL] [Abstract][Full Text] [Related]
2. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.
Florescu DF; Keck MA
Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1171-8. PubMed ID: 25120093
[TBL] [Abstract][Full Text] [Related]
3. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.
Grimley MS; Chemaly RF; Englund JA; Kurtzberg J; Chittick G; Brundage TM; Bae A; Morrison ME; Prasad VK
Biol Blood Marrow Transplant; 2017 Mar; 23(3):512-521. PubMed ID: 28063938
[TBL] [Abstract][Full Text] [Related]
4. The use of brincidofovir for the treatment of mixed dsDNA viral infection.
Camargo JF; Morris MI; Abbo LM; Simkins J; Saneeymehri S; Alencar MC; Lekakis LJ; Komanduri KV
J Clin Virol; 2016 Oct; 83():1-4. PubMed ID: 27513204
[TBL] [Abstract][Full Text] [Related]
5. Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant.
Meena JP; Phillips RS; Kinsey S
J Pediatr Hematol Oncol; 2019 Oct; 41(7):e467-e472. PubMed ID: 30969265
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.
Caruso Brown AE; Cohen MN; Tong S; Braverman RS; Rooney JF; Giller R; Levin MJ
Antimicrob Agents Chemother; 2015 Jul; 59(7):3718-25. PubMed ID: 25733509
[TBL] [Abstract][Full Text] [Related]
7. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies.
Tippin TK; Morrison ME; Brundage TM; Momméja-Marin H
Ther Drug Monit; 2016 Dec; 38(6):777-786. PubMed ID: 27851688
[TBL] [Abstract][Full Text] [Related]
8. Renal Toxicity in Pediatric Patients Receiving Cidofovir for the Treatment of Adenovirus Infection.
Vora SB; Brothers AW; Englund JA
J Pediatric Infect Dis Soc; 2017 Nov; 6(4):399-402. PubMed ID: 28419263
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.
Lee YJ; Neofytos D; Kim SJ; Cheteyan L; Huang YT; Papadopoulos EB; Jakubowski AA; Papanicolaou GA
Transpl Infect Dis; 2018 Dec; 20(6):e12977. PubMed ID: 30120866
[TBL] [Abstract][Full Text] [Related]
11. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Chittick G; Morrison M; Brundage T; Nichols WG
Antiviral Res; 2017 Jul; 143():269-277. PubMed ID: 28093339
[TBL] [Abstract][Full Text] [Related]
12. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.
Paolino K; Sande J; Perez E; Loechelt B; Jantausch B; Painter W; Anderson M; Tippin T; Lanier ER; Fry T; DeBiasi RL
J Clin Virol; 2011 Feb; 50(2):167-70. PubMed ID: 21094081
[TBL] [Abstract][Full Text] [Related]
13. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
El-Haddad D; El Chaer F; Vanichanan J; Shah DP; Ariza-Heredia EJ; Mulanovich VE; Gulbis AM; Shpall EJ; Chemaly RF
Antiviral Res; 2016 Oct; 134():58-62. PubMed ID: 27582067
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
15. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients.
Muller WJ; Levin MJ; Shin YK; Robinson C; Quinones R; Malcolm J; Hild E; Gao D; Giller R
Clin Infect Dis; 2005 Dec; 41(12):1812-6. PubMed ID: 16288409
[TBL] [Abstract][Full Text] [Related]
16. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Voigt S; Hofmann J; Edelmann A; Sauerbrei A; Kühl JS
Transpl Infect Dis; 2016 Oct; 18(5):791-794. PubMed ID: 27482652
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus infection in pediatric transplant recipients: are effective antiviral agents coming our way?
Lopez SMC; Michaels MG; Green M
Curr Opin Organ Transplant; 2018 Aug; 23(4):395-399. PubMed ID: 29846196
[TBL] [Abstract][Full Text] [Related]
18. New drug on the horizon for treating adenovirus.
Wold WS; Toth K
Expert Opin Pharmacother; 2015; 16(14):2095-9. PubMed ID: 26330121
[TBL] [Abstract][Full Text] [Related]
19. Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells.
Tylden GD; Hirsch HH; Rinaldo CH
Antimicrob Agents Chemother; 2015; 59(6):3306-16. PubMed ID: 25801568
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Human Mastadenovirus, the Causal Agent of Pharyngoconjunctival Fever, Epidemic Keratoconjunctivitis, and Hemorrhagic Cystitis in Immunocompromised Individuals, to Brincidofovir.
Hanaoka N; Hazama M; Fukushima K; Fujimoto T
Microbiol Spectr; 2022 Feb; 10(1):e0156921. PubMed ID: 35171015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
